<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01314443</url>
  </required_header>
  <id_info>
    <org_study_id>H10-212</org_study_id>
    <nct_id>NCT01314443</nct_id>
  </id_info>
  <brief_title>Impact of Smoking Cessation and γ-Tocopherol to Restore Vascular Endothelial Function</brief_title>
  <official_title>Cardioprotective Synergy of Smoking Cessation and γ-Tocopherol in Restoring Vascular Endothelial Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Connecticut</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Connecticut</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cigarette smoking is a significant risk factor for cardiovascular disease (CVD) and is the
      leading cause of premature mortality in the US. The detrimental effects of smoking on
      vascular dysfunction are attributed to the effects of smoke itself and the inflammatory
      responses it induces. Smoking cessation restores vascular function by alleviating these
      stress responses. However, smoking cessation with nicotine replacement therapy (NRT), the
      prevailing approach to mitigate tobacco dependence, fails to allow full restoration of
      vascular function. Thus, a critical public health problem exists to understand how NRT
      prevents restoration of vascular function and how these NRT-mediated impairments can be
      overcome by using gamma-tocopherol (g-T) as an innovative co-therapy. The objective of this
      study is to conduct a clinical intervention trial that aims to reduce CVD risk by defining
      how smoking cessation and g-T restore vascular function. The hypothesis is that smoking
      cessation and dietary g-T supplementation will synergistically restore smoking-induced
      impairments in vascular function by ameliorating oxidative/nitrosative stress responses, and
      that g-T will facilitate full restoration of vascular function otherwise precluded by NRT. A
      placebo-controlled, g-T intervention study will be conducted in cigarette smokers undergoing
      nicotine-free or NRT smoking cessation. Prior to and after 24 h and 7 days of placebo or g-T
      administration, vascular function will be evaluated using a non-invasive ultrasound technique
      and an array of antioxidants and biomarkers for vascular inflammation and
      oxidative/nitrosative stress responses will be assessed. Collectively, these studies will
      help identify how vascular function is regulated in individuals undergoing smoking cessation,
      and whether g-T can be used as a strategy to better improve vascular function during smoking
      cessation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While it is well known that smoking cessation reduces the risk of cardiovascular disease
      (CVD), the rate in which CVD risk is normalized is relatively slow. This suggests a need to
      better define co-therapies that target oxidative stress and inflammatory responses that
      otherwise impair vascular function. In this randomized placebo-controlled clinical study,
      smokers undergoing smoking cessation with or without nicotine replacement therapy will
      receive dietary supplementation of gamma-tocopherol (500 mg/day) or placebo for 7 days. Their
      vascular function and biomarkers of CVD risk (inflammatory proteins, antioxidants, oxidized
      lipids) will be assessed prior to, and at 1 day and 7 days during smoking cessation with and
      without gamma-tocopherol supplementation to define potential mechanisms by which
      gamma-tocopherol may accelerate the restoration of vascular function and assist in reducing
      CVD risk.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Change in Brachial Artery Flow-mediated Dilation at Day 7 From Day 0</measure>
    <time_frame>Day 0 and 7 of intervention</time_frame>
    <description>Flow-mediated dilation (FMD) of the brachial artery is measured to assess vascular endothelial function. FMD is obtained by monitoring change in vessel diameter before and after brachial artery occlusion with a blood pressure cuff. The unit of FMD is % and is calculated using the following equation: FMD = [(peak dilation at post occlusion - vessel diameter at preocclusion)/vessel diameter at preocclusion]*100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Plasma Gamma-tocopherol (Vitamin E) at Day 7 From Day 0.</measure>
    <time_frame>Day 0 and 7 of intervention</time_frame>
    <description>Plasma measurements of gamma-tocopherol was assessed in response to smoking cessation and in combination with gamma-tocopherol (vitamin E) supplementation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Plasma Malondialdehyde at Day 7 From Day 0.</measure>
    <time_frame>Day 0 and 7 of intervention</time_frame>
    <description>Plasma measurements of malondialdehyde, a marker of lipid peroxidation was assessed in response to smoking cessation and in combination with gamma-tocopherol (vitamin E) supplementation</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>Placebo + Smoking Cessation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals will quit smoking without use of nicotine replacement therapy (NRT) and ingest a placebo for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Supplement + Smoking Cessation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals will quit smoking without the use of nicotine replacement therapy (NRT) and ingest a gamma-tocopherol supplement for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Nicotine Replacement Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals will quit smoking with the use of nicotine replacement therapy (NRT) and ingest a placebo for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Supplement+Nicotine Replacement Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals will quit smoking with the use of nicotine replacement therapy (NRT) and ingest a gamma-tocopherol supplement for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nicotine Replacement Therapy (NRT)</intervention_name>
    <description>Participants will quit smoking with nicotine patches</description>
    <arm_group_label>Placebo + Nicotine Replacement Therapy</arm_group_label>
    <arm_group_label>Supplement+Nicotine Replacement Therapy</arm_group_label>
    <other_name>Nicotine patches</other_name>
    <other_name>NicoDerm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Gamma-Tocopherol</intervention_name>
    <description>Participants will take gamma-tocopherol (500 mg/d) supplements for 7 days</description>
    <arm_group_label>Supplement + Smoking Cessation</arm_group_label>
    <arm_group_label>Supplement+Nicotine Replacement Therapy</arm_group_label>
    <other_name>Vitamin E</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will take placebo for 7 days</description>
    <arm_group_label>Placebo + Smoking Cessation</arm_group_label>
    <arm_group_label>Placebo + Nicotine Replacement Therapy</arm_group_label>
    <other_name>Corn oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Smoking cessation</intervention_name>
    <description>Participants will quit smoking without any pharmacological aids</description>
    <arm_group_label>Placebo + Smoking Cessation</arm_group_label>
    <arm_group_label>Supplement + Smoking Cessation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female between 18-60 y,

          -  premenopausal status for women

          -  healthy, verified by serum clinical chemistry

          -  stable body weight (±5 lbs) for 2-mo and BMI 19-30 kg/m2

          -  non-nutritional supplement user for &gt;2-mo

          -  free of known diseases including diabetes, CVD, cancer, infections, HIV/AIDS,
             hepatitis, and bleeding disorders

          -  resting blood pressure &lt;140/90 mm Hg;

          -  smokers (≥10 cigarettes/d, ≥1 year)

          -  maintaining normal exercise patterns (&lt;7 h/week) and willingness to avoid exercise 24
             h prior to blood sampling and vascular testing

          -  willingness to ingest a dietary vitamin E supplement (gamma-tocopherol; 500 mg/d) or a
             placebo (composed of tocopherol-free corn oil) daily for 1 week.

        Exclusion Criteria:

          -  serum chemistry outside normal limits

          -  alcohol consumption &gt;3 drinks/d or &gt;10 drinks per week

          -  nutritional supplement user with past 2 months

          -  &gt;7 hours/week of exercise

          -  use of any pharmacological therapy to treat high cholesterol or high blood pressure

          -  pregnancy, lactation, or initiation or change in hormonal birth control within the
             previous 3 mo

          -  use of vasoactive compounds (e.g. erectile dysfunction medication, omega 3-fatty
             acids, niacin)

          -  suffering from major psychiatric illnesses

          -  currently using non-nicotine aids or drugs to quit smoking; or 10) allergy to adhesive
             tape.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard S Bruno, PhD, RD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Connecticut</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Connecticut</name>
      <address>
        <city>Storrs</city>
        <state>Connecticut</state>
        <zip>06269</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Mah E, Pei R, Guo Y, Ballard KD, Barker T, Rogers VE, Parker BA, Taylor AW, Traber MG, Volek JS, Bruno RS. γ-Tocopherol-rich supplementation additively improves vascular endothelial function during smoking cessation. Free Radic Biol Med. 2013 Dec;65:1291-9. doi: 10.1016/j.freeradbiomed.2013.09.016. Epub 2013 Sep 27.</citation>
    <PMID>24075893</PMID>
  </results_reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2011</study_first_submitted>
  <study_first_submitted_qc>March 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2011</study_first_posted>
  <results_first_submitted>December 12, 2012</results_first_submitted>
  <results_first_submitted_qc>March 5, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 6, 2013</results_first_posted>
  <last_update_submitted>January 19, 2015</last_update_submitted>
  <last_update_submitted_qc>January 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Connecticut</investigator_affiliation>
    <investigator_full_name>Richard Bruno</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>smoking cessation</keyword>
  <keyword>gamma-tocopherol</keyword>
  <keyword>nicotine-replacement therapy</keyword>
  <keyword>oxidative stress</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
    <mesh_term>gamma-Tocopherol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment took place in and around the community surrounding the University of Connecticut. Recruitment occurred from 2010-2011.</recruitment_details>
      <pre_assignment_details>Health status of participants was determined from a comprehensive metabolic panel as well as circulating lipid levels. Individuals having serum chemistries outside of acceptable limits were not enrolled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dietary Supplement + Smoking Cessation</title>
          <description>Individuals will ingest gamma-tocopherol (500 mg/d) for 7 days while undergoing smoking cessation without any aids</description>
        </group>
        <group group_id="P2">
          <title>Placebo + Smoking Cessation</title>
          <description>Individuals will ingest placebo for 7 days while undergoing smoking cessation without any aids</description>
        </group>
        <group group_id="P3">
          <title>Dietary Supplement + Nicotine Replacement Therapy</title>
          <description>Individuals will ingest gamma-tocopherol (500 mg/d) for 7 days while undergoing smoking cessation with the use of nicotine replacement therapy</description>
        </group>
        <group group_id="P4">
          <title>Placebo + Nicotine Replacement Therapy</title>
          <description>Individuals will ingest placebo for 7 days while undergoing smoking cessation with the use of nicotine replacement therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>11 participants from the 67 participants enrolled in the study were excluded from all analysis (including baseline). Five participants withdrew from the study before completion and six participants were identified as non-compliant and were removed from the study. Thus, baseline analysis was performed on the remaining 56 participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Supplement + Smoking Cessation</title>
          <description>Individuals will ingest gamma-tocopherol (500 mg/d) for 7 days while undergoing smoking cessation without any aids</description>
        </group>
        <group group_id="B2">
          <title>Placebo + Smoking Cessation</title>
          <description>Individuals will ingest placebo for 7 days while undergoing smoking cessation without any aids</description>
        </group>
        <group group_id="B3">
          <title>Supplement + Nicotine Replacement Therapy</title>
          <description>Individuals will ingest gamma-tocopherol (500 mg/d) for 7 days while undergoing smoking cessation with the use of NRT</description>
        </group>
        <group group_id="B4">
          <title>Placebo + Nicotine Replacement Therapy</title>
          <description>Individuals will ingest placebo for 7 days while undergoing smoking cessation with the use of NRT</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="13"/>
            <count group_id="B4" value="13"/>
            <count group_id="B5" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22" spread="4"/>
                    <measurement group_id="B2" value="22" spread="4"/>
                    <measurement group_id="B3" value="26" spread="8"/>
                    <measurement group_id="B4" value="25" spread="8"/>
                    <measurement group_id="B5" value="24" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change in Brachial Artery Flow-mediated Dilation at Day 7 From Day 0</title>
        <description>Flow-mediated dilation (FMD) of the brachial artery is measured to assess vascular endothelial function. FMD is obtained by monitoring change in vessel diameter before and after brachial artery occlusion with a blood pressure cuff. The unit of FMD is % and is calculated using the following equation: FMD = [(peak dilation at post occlusion - vessel diameter at preocclusion)/vessel diameter at preocclusion]*100.</description>
        <time_frame>Day 0 and 7 of intervention</time_frame>
        <population>Analysis was performed on all participants completing the 7 d intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Dietary Supplement + Smoking Cessation</title>
            <description>Individuals will ingest gamma-tocopherol (500 mg/d) for 7 days while undergoing smoking cessation without any aids</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Smoking Cessation</title>
            <description>Individuals will ingest placebo for 7 days while undergoing smoking cessation without any aids</description>
          </group>
          <group group_id="O3">
            <title>Dietary Supplement + Nicotine Replacement Therapy</title>
            <description>Individuals will ingest gamma-tocopherol (500 mg/d) for 7 days while undergoing smoking cessation with the use of nicotine replacement therapy</description>
          </group>
          <group group_id="O4">
            <title>Placebo + Nicotine Replacement Therapy</title>
            <description>Individuals will ingest placebo for 7 days while undergoing smoking cessation with the use of nicotine replacement therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Brachial Artery Flow-mediated Dilation at Day 7 From Day 0</title>
          <description>Flow-mediated dilation (FMD) of the brachial artery is measured to assess vascular endothelial function. FMD is obtained by monitoring change in vessel diameter before and after brachial artery occlusion with a blood pressure cuff. The unit of FMD is % and is calculated using the following equation: FMD = [(peak dilation at post occlusion - vessel diameter at preocclusion)/vessel diameter at preocclusion]*100.</description>
          <population>Analysis was performed on all participants completing the 7 d intervention</population>
          <units>% of preocclusion diameter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.08" spread="0.61"/>
                    <measurement group_id="O2" value="2.77" spread="0.35"/>
                    <measurement group_id="O3" value="2.97" spread="0.51"/>
                    <measurement group_id="O4" value="2.66" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Plasma Gamma-tocopherol (Vitamin E) at Day 7 From Day 0.</title>
        <description>Plasma measurements of gamma-tocopherol was assessed in response to smoking cessation and in combination with gamma-tocopherol (vitamin E) supplementation.</description>
        <time_frame>Day 0 and 7 of intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dietary Supplement + Smoking Cessation</title>
            <description>Individuals will ingest gamma-tocopherol (500 mg/d) for 7 days while undergoing smoking cessation without any aids</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Smoking Cessation</title>
            <description>Individuals will ingest placebo for 7 days while undergoing smoking cessation without any aids</description>
          </group>
          <group group_id="O3">
            <title>Dietary Supplement + Nicotine Replacement Therapy</title>
            <description>Individuals will ingest gamma-tocopherol (500 mg/d) for 7 days while undergoing smoking cessation with the use of nicotine replacement therapy</description>
          </group>
          <group group_id="O4">
            <title>Placebo + Nicotine Replacement Therapy</title>
            <description>Individuals will ingest placebo for 7 days while undergoing smoking cessation with the use of nicotine replacement therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Plasma Gamma-tocopherol (Vitamin E) at Day 7 From Day 0.</title>
          <description>Plasma measurements of gamma-tocopherol was assessed in response to smoking cessation and in combination with gamma-tocopherol (vitamin E) supplementation.</description>
          <units>microM</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.30" spread="0.98"/>
                    <measurement group_id="O2" value="-0.10" spread="0.21"/>
                    <measurement group_id="O3" value="7.28" spread="1.57"/>
                    <measurement group_id="O4" value="-0.24" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Plasma Malondialdehyde at Day 7 From Day 0.</title>
        <description>Plasma measurements of malondialdehyde, a marker of lipid peroxidation was assessed in response to smoking cessation and in combination with gamma-tocopherol (vitamin E) supplementation</description>
        <time_frame>Day 0 and 7 of intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dietary Supplement + Smoking Cessation</title>
            <description>Individuals will ingest gamma-tocopherol (500 mg/d) for 7 days while undergoing smoking cessation without any aids</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Smoking Cessation</title>
            <description>Individuals will ingest placebo for 7 days while undergoing smoking cessation without any aids</description>
          </group>
          <group group_id="O3">
            <title>Dietary Supplement + Nicotine Replacement Therapy</title>
            <description>Individuals will ingest gamma-tocopherol (500 mg/d) for 7 days while undergoing smoking cessation with the use of nicotine replacement therapy</description>
          </group>
          <group group_id="O4">
            <title>Placebo + Nicotine Replacement Therapy</title>
            <description>Individuals will ingest placebo for 7 days while undergoing smoking cessation with the use of nicotine replacement therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Plasma Malondialdehyde at Day 7 From Day 0.</title>
          <description>Plasma measurements of malondialdehyde, a marker of lipid peroxidation was assessed in response to smoking cessation and in combination with gamma-tocopherol (vitamin E) supplementation</description>
          <units>microM</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.05"/>
                    <measurement group_id="O2" value="-0.06" spread="0.03"/>
                    <measurement group_id="O3" value="-0.04" spread="0.04"/>
                    <measurement group_id="O4" value="-0.07" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dietary Supplement + Smoking Cessation</title>
          <description>Individuals will ingest gamma-tocopherol (500 mg/d) for 7 days while undergoing smoking cessation without any aids</description>
        </group>
        <group group_id="E2">
          <title>Placebo + Smoking Cessation</title>
          <description>Individuals will ingest placebo for 7 days while undergoing smoking cessation without any aids</description>
        </group>
        <group group_id="E3">
          <title>Dietary Supplement + Nicotine Replacement Therapy</title>
          <description>Individuals will ingest gamma-tocopherol (500 mg/d) for 7 days while undergoing smoking cessation with the use of nicotine replacement therapy</description>
        </group>
        <group group_id="E4">
          <title>Placebo + Nicotine Replacement Therapy</title>
          <description>Individuals will ingest placebo for 7 days while undergoing smoking cessation with the use of nicotine replacement therapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Very few women were enrolled thereby precluding any assessment of potential gender differences for our outcome variables.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Richard Bruno, PhD, RD</name_or_title>
      <organization>Ohio State University</organization>
      <phone>614-292-5522</phone>
      <email>bruno.27@osu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

